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P U B L I S H E D B Y E L S E V I E R I N C .LettersCharacterization of the
First PCSK9 Gain of
Function HomozygoteGain of function (GOF) mutations in proprotein con-
vertase subtilisin kexin type 9 (PCSK9) are a rare
cause of familial hypercholesterolemia (FH). We
identiﬁed a child with a clinical diagnosis of FH with
2 novel putative PCSK9 GOF missense variants
(p.[(Ala62Asp)]; [(Pro467Ala)]), and no mutation in
the low-density lipoprotein (LDL) receptor (LDLR) or
in apolipoprotein B100 (APOB) genes. The proband
was referred to the Portuguese FH Study (1) at age 11
and presented a total cholesterol of 316 mg/dl
and low-density lipoprotein cholesterol (LDL-C) of
234 mg/dl on a strict diet. The phenotype presented by
all PCSK9 heterozygous carriers within this large
pedigree is similar to APOB heterozygous carriers
(LDL-C, 198.75  14.98 mg/dl vs. LDL-C, 211.57  42.02
mg/dl; p ¼ 0.227) but signiﬁcantly different than het-
erozygous LDLR carriers (LDL-C, 198.75  14.98 mg/dl
vs. LDL-C, 230.63  76.50 mg/dl; p ¼ 0.012) when
comparing the relatives’ phenotype in our cohort.
To characterize these variants, we ﬁrst transfected
HEK293 cells (which do not endogenously produce
PCSK9) with either wild-type, p.(Ala62Asp), or
p.(Pro467Ala) PCSK9 expression vectors. The GOF
p.(Asp374Tyr) PCSK9 was used as positive control.
The cellular expression and secretion patterns of
wild-type and all 3 mutants were similar (not shown).
We next transfected HepG2 cells with these vectors
and assessed cell surface LDLR expression as well as
ﬂuorescent LDL uptake by ﬂow cytometry (2).
Compared with nontransfected cells (baseline), cells
expressing wild-type PCSK9 had reduced LDLR
(30%; p < 0.05), and cells expressing either
p.(Asp374Tyr), p.(Ala62Asp), or p.(Pro467Ala) PCSK9
had further reduced LDLR cell surface expression
(52%, 46%, and 56%, respectively; p < 0.05 vs.
wild type, all) (Figure 1A). Likewise, ﬂuorescent LDL
uptake was signiﬁcantly lower (35% vs. baseline) in
cells expressing any 1 of the 3 PCSK9 variants
compared with cells expressing wild-type PCSK9
(20% vs. baseline) (not shown). We ascertained byWestern blot and enzyme-linked immunosorbent
assay that PCSK9 expression was similar in HepG2
cells expressing wild-type or each of the PCSK9 vari-
ants (not shown). These data indicate that
p.(Ala62Asp) and p.(Pro467Ala) are genuine PCSK9
GOF variants.
To ascertain the functionality of the LDLR in pa-
tients carrying p.(Ala62Asp) and/or p.(Pro467Ala)
PCSK9 variants, we performed a series of analyses of
their lymphocytes. Statin treatment similarly
increased baseline LDLR expression at the surface of
lymphocytes isolated from the proband, her hetero-
zygous parents, and a normolipidemic donor. Re-
combinant PCSK9 similarly reduced LDLR expression
by as much as 75% to 85% in statin-treated lympho-
cytes, irrespective of the donor. The PCSK9 inhibitor
alirocumab reversed these effects in each experi-
mental condition (Figure 1B). The cellular uptake of
ﬂuorescent LDL in those cells paralleled the levels of
cell surface LDLR expression in control and the pa-
tient’s lymphocytes alike (not shown). Thus, the
LDLR of the proband and of her parents is normally
expressed and fully functional, underscoring the
causative link that exists between their FH phenotype
and their PCSK9 mutations. It is noteworthy that
despite ongoing statin treatment, circulating PCSK9
levels of the proband, her father, and her mother
were found within the normal range for age and sex at
148, 209, and 250 ng/ml, respectively (3). This further
underpins that both PCSK9 p.(Asp62Ala) and
p.(Pro467Ala) are bona ﬁde GOF variants.
We fully characterize here the ﬁrst compound
heterozygote FH patient with 2 PCSK9 GOF variants.
The experiments conducted on the proband’s lym-
phocytes clearly suggest that this patient should
respond particularly well to a treatment combining a
statin and a PCSK9 inhibitor. This child (now 15 years
old) is currently treated with atorvastatin 10 mg/day,
with her last LDL-C levels at 88 mg/dl. However, as
seen in other FH children, the phenotype is always
milder than in adulthood (4). Because her phenotype
can worsen over time, these novel therapeutic op-
tions (a statin with a PCSK9 inhibitor) will probably
allow her to maintain her LDL values below target
levels for high-risk patients. This patient will be very
interesting to follow in the coming years.
FIGURE 1 Characterization of 2 Novel PCSK9 Gain of Function Variants
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(A) Cell surface LDLR expression in HepG2 transfected with wild-type, p.(Asp374Tyr), p.(Ala62Asp), and p.(Pro467Ala) PCSK9 variants.
*p < 0.05 versus nontransfected; **p < 0.05 versus wild-type PCSK9. (B) Cell surface LDLR expression in lymphocytes from a control donor,
the father (PCSK9-Pro467Ala carrier), the mother (PCSK9-Ala62Asp carrier), and the proband (PCSK9-Ala62Asp and PCSK9-Pro467Ala
compound heterozygote carrier). Values represent the mean  SD of triplicate determinations. *p < 0.05 versus no statin treatment;
#p < 0.05 versus mevastatin only treatment; **p < 0.05 versus mevastatin þ PCSK9-Asp374Cys. LDLR ¼ low-density lipoprotein receptor;
MFI ¼ mean ﬂuorescence intensity (arbitrary units).
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Survival After
Liver Transplantation
for Familial
Transthyretin AmyloidosisFamilial transthyretin amyloidosis (ATTR) is a rare,
life-threatening, autosomal dominant disease in-
volving mainly the heart and the peripheral nervous
system due to a point mutation of the transthyretin
(TTR) gene. By removing the main source of the
mutated TTR, liver transplantation (LT) has become
the standard treatment for ATTR (1). Because the
demand for liver grafts exceeds the number of avail-
able organs and because new treatments have
recently emerged, screening patients at high risk of
death after LT is critical (2).
We identiﬁed 215 consecutive patients who un-
derwent LT between 1993 and 2011. The diagnosis
was made by the observation of both amyloid
deposits in biopsy specimens and a TTR mutation.
The pre-operative evaluation included physical ex-
amination, electrocardiography, echocardiography,
autonomic dysfunction score, and polyneuropathy
disability score (PND) calculation. The primary
study endpoint was all-cause mortality after LT. Theprognostic model predicting the individual probabil-
ity of death within the ﬁrst 5 years after LT was
developed from the Cox proportional hazards model
and was internally validated using bootstrapping.
At the time of LT, patients’ median age was 43 years,
61% were men, and 69% carried the Val30Met
mutation. There were 81% patients in New York Heart
Association (NYHA) functional class I, 40% had con-
duction disorders, 36% had a $12-mm interventricular
septum on the echocardiograms, and the median left
ventricular ejection fraction was 65%. All patients
presented with neurological manifestations of ATTR:
isolated sensory disturbances (PND I: 61%), difﬁculties
with walking (PND II: 22%), and the need for cane(s)
to walk (PND III: 17%). The vegetative score was ab-
normal in 82%, and 59% had orthostatic hypotension.
Over a median follow-up of 5.9 years after LT, 84
patients died, and cardiac events were the leading
cause of death (38% of all deaths). The signiﬁcant
pejorative factors were PND score $III (hazard ratio
[HR]: 1.75; 95% conﬁdence interval [CI]: 1.04 to 2.96;
p ¼ 0.036), orthostatic hypotension (HR: 2.26; 95%
CI: 1.39 to 4.22; p ¼ 0.001), NYHA functional class >I
(HR: 2.25; 95% CI: 1.18 to 4.27; p ¼ 0.014), QRS
duration $120 ms (HR: 1.90; 95% CI: 1.05 to 3.43;
p¼ 0.035), thickened interventricular septum (for each
millimeter: HR: 1.12; 95% CI: 1.04 to 1.20; p ¼ 0.002).
The individual probability of death at 5 years was
calculated as Pdeath at 5 years ¼ 1  0.735e(coeff sum  1.27810),
where coeff sum ¼ (0.57423  PND score $III) þ
(0.77339  orthostatic hypotension) þ (0.91192 
NYHA functional class >I) þ (0.60378  QRS $120
ms) þ (0.14589  [interventricular septum thickness
 6]). Risk can be computed using the online
calculator. The calibration slope was 0.89 (95% CI:
0.64 to 1.15), the C-index of Harrel was 0.68 (95% CI:
0.45 to 0.88), and the concordance probability esti-
mate was 0.71 (95% CI: 0.67 to 0.75). The area under
the receiver-operating characteristic curve for the
5-year survival was 0.80, and signiﬁcant differences
of survival were found according to the 5-year
death risk (Figure 1). Pre-operative identiﬁcation of a
high-risk proﬁle (risk >50%) was retrospectively
documented in 40 of 215 patients (19%).
The risk score was built from variables that
measured the cardiac and neurological status
regardless of mutation type. Therefore, our proposed
score should be useful to gauge the risk of patients
with rare variants of TTR and to take into account the
phenotypic variability encountered among patients
with a similar mutation. The study population was
representative of a region where ATTR is not endemic
and the 74% 5-year survival of our patients in line
with the 77% previously reported (3). Previous reports
